{
    "clinical_study": {
        "@rank": "6455", 
        "acronym": "IN CONTROL", 
        "arm_group": [
            {
                "arm_group_label": "Real-time continuous glucose monitor", 
                "arm_group_type": "Active Comparator", 
                "description": "16 weeks use of a real-time continuous glucose monitor"
            }, 
            {
                "arm_group_label": "Continuous glucose monitor", 
                "arm_group_type": "Placebo Comparator", 
                "description": "16 weeks use of a (blinded, retrospective) continuous glucose monitor"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine what the effects are of real-time continuous\n      glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus\n      and impaired hypoglycemia awareness."
        }, 
        "brief_title": "The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 1 Diabetes Mellitus", 
            "Impaired Hypoglycemia Awareness", 
            "Hypoglycemia Unawareness"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Hypoglycemia", 
                "Unconsciousness"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators hypothesize that the use of RT-CGM, relative to a control intervention\n      using masked CGM, will result in improvement of various measures of glycemia and indicators\n      of quality of life, reduce the occurrence of hypoglycemia and hyperglycemia and restore\n      hypoglycemia awareness in T1DM patients with IHA. We will test this hypothesis by addressing\n      the following research questions:\n\n      What is the effect of 16 weeks of RT-CGM use, versus 16 weeks of CGM use, in patients with\n      T1DM and IHA on\n\n        1. (primary objective:) time spent in euglycemia\n\n        2. (secondary objectives:)\n\n             -  (diabetes-specific) markers of QoL, covering diabetes-related emotional distress\n                (PAID-5), fear of hypoglycemia (HFS-2), self-efficacy (CIDS), health status (EQ5D)\n                and emotional well-being (WHO-5)\n\n             -  other glycemia variables, including HbA1c and time spent in hypo- and -\n                hyperglycemia ranges\n\n             -  the incidence and duration of hypoglycemic episodes\n\n             -  changes in hypoglycemia awareness score according to Gold et al.,\n\n        3. (tertiary objectives:)\n\n             -  measures of glucose variability\n\n             -  the autonomic nervous system balance\n\n             -  the duration of wear of the RT-CGM device\n\n             -  patients' therapy adjustments during the interventions\n\n             -  hypoglycemia awareness scores according to Clarke et al.\n\n             -  satisfaction with use of CGM\n\n             -  the number of contact moments not planned according to the study schedule\n\n             -  absence of work of patient (and spouse)\n\n             -  the global estimated costs of use of health care"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  T1DM, diagnosed according to ADA criteria regardless duration\n\n          -  Use of multiple daily injections of insulin (with a basal insulin injection and bolus\n             injections) or continuous subcutaneous insulin infusion\n\n          -  Any HbA1c\n\n          -  Age between 18 and 70 years old (inclusive)\n\n          -  IHA according to the questionnaire by Gold et al.\n\n          -  Performing at least 3 SMBG/day or 21 SMBG/week\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes mellitus\n\n          -  History of (recent) major renal, liver, or (ischemic) heart disease (including\n             cardiac conduction disorders)\n\n          -  Current untreated proliferative diabetic retinopathy\n\n          -  Current (treatment for) malignancy\n\n          -  Current use of non-selective beta-blockers\n\n          -  Current psychiatric disorders, including schizophrenia, bipolar disorder, anorexia\n             nervosa or bulimia nervosa\n\n          -  Substance abuse or alcohol abuse (men >21 units/week, women >14 units/week)\n\n          -  Current pregnancy or intention to conceive\n\n          -  Current use of RT-CGM other than for short term (i.e. diagnostic use or use shorter\n             than 3 consecutive months)\n\n          -  Hearing or vision impairment hindering perceiving of glucose display and alarms, or\n             otherwise incapable of using a (RT-)CGM, in the opinion of the investigator\n\n          -  Poor commandment of the Dutch language or any (mental) disorder that precludes full\n             understanding of the purpose and instructions of the study\n\n          -  Participation in another clinical study\n\n          -  Known or suspected allergy to trial product or related products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787903", 
            "org_study_id": "DC2012INCONTROL01"
        }, 
        "intervention": {
            "arm_group_label": "Real-time continuous glucose monitor", 
            "intervention_name": "Real-time continuous glucose monitor", 
            "intervention_type": "Device", 
            "other_name": "MiniMed Paradigm\u00ae Veo\u2122-system"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 1 diabetes mellitus", 
            "Impaired hypoglycemia awareness", 
            "Hypoglycemia unawareness", 
            "Real-time continuous glucose monitoring", 
            "Glucose control"
        ], 
        "lastchanged_date": "March 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "state": "Noord-Holland", 
                    "zip": "1081"
                }, 
                "name": "VU University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Susanne J Kleijer, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michaela Diamant, MD PHD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Real-time Continuous Glucose Monitoring on Glycemia and Quality of Life in Patients With Type 1 Diabetes Mellitus and Impaired Hypoglycemia Awareness", 
        "other_outcome": [
            {
                "description": "RT-CGM derived measures of glucose variability, e.g. SD, MODD, CONGA", 
                "measure": "Glucose variability", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "The autonomic nervous system balance", 
                "measure": "ANS balance", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "The duration of wear of the RT-CGM device", 
                "measure": "Sensor wear duration", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "The therapy adjustments made by patients during the interventions", 
                "measure": "Therapy adjustments", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "Hypoglycemia awareness scores according to Clarke et al.", 
                "measure": "Hypoglycemia awareness score", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "Satisfaction with use of CGM", 
                "measure": "RT-CGM satisfaction", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }
        ], 
        "overall_contact": {
            "email": "s.kleijer@vumc.nl", 
            "last_name": "Susanne J Kleijer, MD", 
            "phone": "+31 20 4444588"
        }, 
        "overall_contact_backup": {
            "email": "m.diamant@vumc.nl", 
            "last_name": "Michaela Diamant, MD PHD FRCPE", 
            "phone": "+31 20 4440534"
        }, 
        "overall_official": {
            "affiliation": "VU University Medical Center", 
            "last_name": "Michaela Diamant, MD PhD FRCPE", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The mean difference in time spent in the euglycemic range (interstitial glucose >3.9-<10.0 mmol/L), expressed as hours/day between the two 16-week intervention periods, i.e. RT-CGM versus masked CGM in patients with T1DM and IHA.", 
            "measure": "Time spent in the euglycemic range", 
            "safety_issue": "No", 
            "time_frame": "45 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787903"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VU University Medical Center", 
            "investigator_full_name": "M. Diamant", 
            "investigator_title": "MD PhD FRCPE", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "(diabetes-specific) markers of QoL, covering diabetes-related emotional distress (PAID-5), fear of hypoglycemia (HFS-2), self-efficacy (CIDS), health status (EQ5D) and emotional well-being (WHO-5)", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "Other glycemia variables, including HbA1c and time spent in hypo- and hyperglycemia ranges", 
                "measure": "Glycemia variables", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "The incidence and duration of hypoglycemic episodes", 
                "measure": "Hypoglycemic episodes", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }, 
            {
                "description": "Changes in hypoglycemia awareness score according to Gold et al.", 
                "measure": "Changes in hypoglycemia awareness score", 
                "safety_issue": "No", 
                "time_frame": "45 weeks"
            }
        ], 
        "source": "VU University Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "VU University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}